American CryoStem Corporation (CRYO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
American CryoStem Corporation (CRYO) trades at $0.00 with AI Score 46/100 (Grade C). American CryoStem Corporation specializes in developing technologies from adipose tissue for regenerative medicine. Market cap: $4,428, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CRYO: CRYO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CRYO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CRYO: the 1 perspectives are evenly split.
How is this calculated? →American CryoStem Corporation (CRYO) Healthcare & Pipeline Overview
American CryoStem Corporation (CRYO) is a biotechnology firm dedicated to advancing regenerative medicine through innovative adipose-derived technologies, including tissue preservation and stem cell therapies, positioning itself as a niche player in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for CRYO?
American CryoStem Corporation is positioned to capitalize on the growing demand for regenerative medicine solutions, particularly in the area of adipose-derived therapies. The market for stem cell therapies is projected to reach approximately $20 billion by 2025, driven by advancements in technology and increasing acceptance of these treatments. The company's unique offerings, including the CELLECT system and ATGRAFT service, provide a competitive edge by streamlining tissue processing and enhancing clinical outcomes. However, the company faces challenges such as a negative profit margin of -13985.4%, which highlights the need for improved operational efficiency and revenue generation. As the market evolves, American CryoStem's ability to secure funding and navigate regulatory hurdles will be crucial for its sustained growth and success.
Based on FMP financials and quantitative analysis
CRYO Key Highlights
- Market Cap of 4K indicates a micro-cap status, potentially appealing to niche investors.
- Profit Margin of -13985.4% reflects significant operational challenges that need addressing.
- Gross Margin of 34.1% suggests potential for profitability if revenue can be increased.
- Beta of 11.42 indicates high volatility, which may attract risk-tolerant investors.
- No dividend yield signifies a focus on reinvestment rather than returning capital to shareholders.
Who Are CRYO's Competitors?
CRYO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CRYO's Key Strengths?
- Established expertise in adipose-derived technologies.
- Innovative product offerings that address niche market needs.
- Strong potential for growth in the expanding regenerative medicine sector.
What Are CRYO's Weaknesses?
- Negative profit margin indicating operational challenges.
- Limited workforce of only 4 employees may hinder scalability.
- Dependence on niche market may limit revenue diversification.
What Could Drive CRYO Stock Higher?
- Increased adoption of CELLECT and ATGRAFT services as awareness of adipose-derived therapies grows.
- Development of proprietary products like ATCELL and ACSelerat that cater to the regenerative medicine market.
- Potential partnerships with healthcare providers to expand service offerings and market reach.
What Are the Key Risks for CRYO?
- Financial-distress signal — its Altman Z-Score of -41.21 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges in the biotechnology sector may impact product development timelines.
- High volatility in stock price could deter institutional investment.
- Limited workforce may restrict operational scalability and growth.
What Are the Growth Opportunities for CRYO?
- Growth opportunity 1: The global stem cell therapy market is projected to reach $20 billion by 2025, driven by increasing acceptance and advancements in technology. American CryoStem's focus on adipose-derived therapies positions it well to capture a significant share of this expanding market, particularly as more physicians adopt these innovative solutions in clinical practice.
- Growth opportunity 2: The CELLECT system enhances tissue sample collection and storage efficiency, addressing a critical need in regenerative medicine. As healthcare providers increasingly seek streamlined processes to improve patient outcomes, the adoption of CELLECT could lead to increased sales and market penetration, particularly in hospitals and specialized clinics.
- Growth opportunity 3: The ATGRAFT service offers comprehensive solutions for harvesting and preserving adipose tissue, appealing to a growing number of practitioners in regenerative medicine. With the increasing demand for personalized medical treatments, this service could see substantial growth as more healthcare providers recognize the value of adipose-derived products in their practices.
- Growth opportunity 4: American CryoStem's proprietary ATCELL product line, featuring adipose-derived stem cells, is positioned to benefit from the rising interest in stem cell therapies. As research continues to validate the efficacy of these treatments, demand for ATCELL could increase, providing a significant revenue stream for the company.
- Growth opportunity 5: The contract manufacturing services offered by American CryoStem, including the development of specialized formulations like Autokine-CM, present an opportunity to diversify revenue streams. As the market for customized healthcare products expands, the ability to provide tailored solutions could enhance the company's competitive position and drive growth.
What Opportunities Does CRYO Have?
- Growing global interest in stem cell therapies and regenerative medicine.
- Potential for increased adoption of CELLECT and ATGRAFT services.
- Expansion of contract manufacturing services to diversify revenue streams.
What Threats Does CRYO Face?
- Regulatory challenges in the biotechnology sector may impact operations.
- High volatility in stock price could deter potential investors.
- Competition from larger biotechnology firms with more resources.
What Are CRYO's Competitive Advantages?
- Specialization in adipose-derived technologies differentiates American CryoStem from competitors.
- Proprietary products like CELLECT and ATGRAFT create barriers to entry for new entrants.
- Strong focus on innovation and quality enhances brand reputation in the healthcare sector.
What Does CRYO Do?
Founded in 1987, American CryoStem Corporation (ACSC) is headquartered in Eatontown, New Jersey, and has established itself as a leader in the biotechnology sector, focusing on the development, commercialization, and licensing of technologies derived from adipose (fat) tissue. The company’s flagship offering, the CELLECT system, is designed to optimize the collection, transportation, and storage of tissue samples, thereby streamlining processes for medical practitioners. In addition to CELLECT, ACSC provides the ATGRAFT service, which facilitates the harvesting, processing, and preservation of adipose tissue, empowering physicians to offer diverse options for tissue products and cellular banking to their patients. The ATCELL product line features proprietary adipose-derived stem cells, while the ACSelerat cell culture media is specifically engineered to enhance the growth of human stromal cells. Furthermore, American CryoStem extends its capabilities through contract manufacturing services, producing specialized formulations such as Autokine-CM, an anti-aging topical product, and a unique range of autologous skincare solutions. The company’s commitment to innovation and quality positions it well within the regenerative medicine market, which is experiencing significant growth as interest in stem cell therapies continues to rise.
What Products and Services Does CRYO Offer?
- Develops and commercializes technologies derived from adipose tissue.
- Offers the CELLECT system for efficient tissue sample collection and storage.
- Provides the ATGRAFT service for harvesting and preserving adipose tissue.
- Markets proprietary adipose-derived stem cells under the ATCELL brand.
- Produces ACSelerat cell culture media to support human stromal cell growth.
- Offers contract manufacturing services for specialized healthcare formulations.
How Does CRYO Make Money?
- Generates revenue through the sale of proprietary products and services in regenerative medicine.
- Provides contract manufacturing services to other healthcare companies.
- Licenses technology related to adipose-derived therapies and products.
What Industry Does CRYO Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in regenerative medicine. The global market for stem cell therapy is expected to grow at a CAGR of over 10% from 2021 to 2028, driven by advancements in technology and increasing prevalence of chronic diseases. American CryoStem operates within this dynamic landscape, focusing on adipose-derived technologies, which are gaining traction due to their versatility and potential for personalized medicine. The competitive landscape includes various players, but American CryoStem's specialized focus on adipose tissue positions it uniquely among broader biotechnology firms.
Who Are CRYO's Key Customers?
- Healthcare providers including hospitals and clinics specializing in regenerative medicine.
- Physicians offering personalized medical treatments utilizing adipose-derived products.
- Research institutions conducting studies on stem cell therapies and regenerative medicine.
F-Score 3/9Financial Health
American CryoStem Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.21 places it in the distress zone, a signal of elevated financial risk.
CRYO Valuation & Market Position
With a 4K market cap, American CryoStem Corporation sits in the micro-cap segment of the market. Relative to its peer group, CRYO's quantitative score of 46/100 is below the peer average of 77/100.
ROE 254%Key Financial Metrics
Return on equity for American CryoStem Corporation stands at 253.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
American CryoStem Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Eatontown, US. The company is led by CEO John S. Arnone. CRYO has traded publicly since 2010.
CRYO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and their applications in regenerative medicine.
- Increased media coverage around stem cell therapy has raised awareness, driving interest and engagement among investors and consumers alike.
- Strategic partnerships announced recently could enhance market reach and operational capabilities, positioning the company for growth.
Bear Case
- Concerns regarding regulatory hurdles in the stem cell industry persist, causing caution among potential investors and stakeholders.
- Negative sentiment from some community members reflects skepticism about the company's ability to scale operations effectively in a competitive market.
- Recent quarterly results may have disappointed some investors, leading to a reevaluation of growth expectations and future profitability.
- Market volatility and economic uncertainty could impact funding opportunities, raising doubts about the company's financial stability in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CRYO Latest News
No recent news available for CRYO.
CRYO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRYO.
Price Targets
Wall Street price target analysis for CRYO.
CRYO MoonshotScore
What does this score mean?
The MoonshotScore rates CRYO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John S. Arnone
CEO
John S. Arnone has been at the helm of American CryoStem Corporation since its inception in 1987. With a strong background in biotechnology and healthcare, he has guided the company through its development and commercialization phases. His leadership has been instrumental in establishing ACSC's focus on adipose-derived technologies and regenerative medicine.
Track Record: Under John S. Arnone's leadership, American CryoStem has developed key products such as the CELLECT system and ATGRAFT service, positioning the company as a niche player in the biotechnology sector. His strategic vision has enabled ACSC to navigate challenges and capitalize on emerging trends in regenerative medicine.
CRYO OTC Market Information
The OTC Other tier represents companies that trade on over-the-counter markets but do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier often includes smaller, less liquid companies, which may have less stringent reporting and regulatory requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may hinder transparency for investors.
- Potential for higher volatility and less liquidity compared to listed stocks.
- Regulatory scrutiny may increase as the company grows, impacting operations.
- Review recent financial statements and disclosures for accuracy.
- Assess the company's compliance with OTC reporting requirements.
- Evaluate the competitive landscape and market position.
- Monitor regulatory developments affecting the biotechnology sector.
- Investigate the management team's track record and experience.
- Established history since 1987 demonstrates longevity in the market.
- Innovative product offerings indicate a commitment to research and development.
- Partnerships or collaborations with reputable healthcare providers can enhance credibility.
American CryoStem Corporation Healthcare Stock: Key Questions Answered
What does American CryoStem Corporation do?
American CryoStem Corporation specializes in the development and commercialization of technologies derived from adipose tissue for applications in regenerative and personalized medicine. Key offerings include the CELLECT system for tissue sample collection and the ATGRAFT service for harvesting and preserving adipose tissue, alongside proprietary stem cell products and contract manufacturing services.
What are the main risks for CRYO?
American CryoStem faces several risks, including regulatory challenges that could impact product development and operational timelines. Additionally, the company's negative profit margin indicates financial instability, which may affect its ability to secure funding. The high volatility of its stock price could deter potential investors, while a limited workforce may hinder scalability.
What revenue streams does American CryoStem Corporation have in healthcare?
American CryoStem Corporation generates revenue through multiple streams, including the sale of proprietary products like the CELLECT system and ATGRAFT service, which cater to healthcare providers in regenerative medicine. Additionally, the company offers contract manufacturing services for specialized formulations, allowing it to diversify its revenue base and meet the needs of various customer segments.
What are the key factors to evaluate for CRYO?
American CryoStem Corporation (CRYO) holds an AI score of 46/100 (low). Not financial advice.
How frequently does CRYO data refresh on this page?
CRYO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CRYO's recent stock price performance?
American CryoStem Corporation (CRYO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established expertise in adipose-derived technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CRYO overvalued or undervalued right now?
Valuing American CryoStem Corporation (CRYO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CRYO?
Before investing in American CryoStem Corporation (CRYO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to OTC classification and disclosure status.